These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 30980209)
21. The Global Need for a Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer. Blackwell K; Gligorov J; Jacobs I; Twelves C Clin Breast Cancer; 2018 Apr; 18(2):95-113. PubMed ID: 29525430 [TBL] [Abstract][Full Text] [Related]
22. Totality of Scientific Evidence in the Development of ABP 980, a Biosimilar to Trastuzumab. Kolberg HC; Colleoni M; Santi P; Demetriou GS; Segui-Palmer MA; Fujiwara Y; Hurvitz SA; Hanes V Target Oncol; 2019 Dec; 14(6):647-656. PubMed ID: 31620980 [TBL] [Abstract][Full Text] [Related]
23. Biosimilars are coming: ready or not. Zalcberg J Intern Med J; 2018 Sep; 48(9):1027-1034. PubMed ID: 29984453 [TBL] [Abstract][Full Text] [Related]
24. Trastuzumab biosimilars vs trastuzumab originator in the treatment of HER2-positive breast cancer: a systematic review and network meta-analysis. Liu T; Liu D; Jin Y; Dong M Immunopharmacol Immunotoxicol; 2022 Dec; 44(6):809-815. PubMed ID: 35708278 [TBL] [Abstract][Full Text] [Related]
25. Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer: A Systematic Review and Meta-analysis. Bloomfield D; D'Andrea E; Nagar S; Kesselheim A JAMA Oncol; 2022 Apr; 8(4):537-545. PubMed ID: 35113135 [TBL] [Abstract][Full Text] [Related]
26. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer. Taïeb J; Aranda E; Raouf S; Dunn H; Arnold D Clin Colorectal Cancer; 2021 Mar; 20(1):42-51.e3. PubMed ID: 33243618 [TBL] [Abstract][Full Text] [Related]
27. Biosimilar Use in Breast Cancer Treatment: A National Survey of Brazilian Oncologists' Opinions, Practices, and Concerns. Resende HM; Ladislau L; Cardoso ACF; Brandão JDP; Assis BR; Cardoso P; Marassi PHA; Castilho V JCO Glob Oncol; 2021 Aug; 7():1316-1324. PubMed ID: 34415791 [TBL] [Abstract][Full Text] [Related]
28. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer. Thill M Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719 [TBL] [Abstract][Full Text] [Related]
29. [Biosimilar drugs in oncology]. Levêque D Bull Cancer; 2016 Mar; 103(3):294-8. PubMed ID: 26832422 [TBL] [Abstract][Full Text] [Related]
30. Clinical trials for authorized biosimilars in the European Union: a systematic review. Mielke J; Jilma B; Koenig F; Jones B Br J Clin Pharmacol; 2016 Dec; 82(6):1444-1457. PubMed ID: 27580073 [TBL] [Abstract][Full Text] [Related]
31. The rise of oncology biosimilars: from process to promise. Verrill M; Declerck P; Loibl S; Lee J; Cortes J Future Oncol; 2019 Oct; 15(28):3255-3265. PubMed ID: 31441323 [TBL] [Abstract][Full Text] [Related]
32. Biosimilars: a systematic review of published and ongoing clinical trials of antipsoriatics in chronic inflammatory diseases. Nast A; Rosumeck S; Seidenschnur K J Dtsch Dermatol Ges; 2015 Apr; 13(4):294-300. PubMed ID: 25819235 [TBL] [Abstract][Full Text] [Related]
33. Biosimilars in ulcerative colitis: When and for who? Ilias A; Gonczi L; Kurti Z; Lakatos PL Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937 [TBL] [Abstract][Full Text] [Related]
34. Talking to patients about biosimilars. Janjigian YY; Bissig M; Curigliano G; Coppola J; Latymer M Future Oncol; 2018 Oct; 14(23):2403-2414. PubMed ID: 29856243 [TBL] [Abstract][Full Text] [Related]
35. A descriptive analysis of real-world oncology biosimilar use in Japan. Roth JA; Rahshenas M; Nowacki G; Masurkar N; Shelbaya A; Tajima K; Dorman S; Ono C Future Oncol; 2024; 20(25):1837-1850. PubMed ID: 38864611 [TBL] [Abstract][Full Text] [Related]
36. Biosimilars: what the oncologist should know. Thill M; Thatcher N; Hanes V; Lyman GH Future Oncol; 2019 Apr; 15(10):1147-1165. PubMed ID: 30793950 [TBL] [Abstract][Full Text] [Related]
37. Comparative Effectiveness and Safety of Trastuzumab Biosimilars to Herceptin for Adjuvant Treatment of HER2+ Breast Cancer. Muñoz C; Tai X; Arias J; Eisen A; Chaudhry M; Gavura S; Chan KKW Curr Oncol; 2024 Mar; 31(3):1633-1644. PubMed ID: 38534957 [No Abstract] [Full Text] [Related]
38. Sample Size for Biosimilar Trials: In Defense of Synthesis. Clark T; Jo SJ; Phillips A Ther Innov Regul Sci; 2018 May; 52(3):300-305. PubMed ID: 29714537 [TBL] [Abstract][Full Text] [Related]
39. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects. Declerck P; Danesi R; Petersel D; Jacobs I Drugs; 2017 Apr; 77(6):671-677. PubMed ID: 28258517 [TBL] [Abstract][Full Text] [Related]
40. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial. Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E; JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]